BerGenBio

BERGENBIO TO PRESENT AT CARNEGIE VIRTUAL NORDIC HEALTHCARE SEMINAR

Bergen, Norway, 17 March 2022 - BerGenBio ASA (OSE: BGBIO), a clinical-stage

biopharmaceutical company developing novel, selective AXL kinase inhibitors for

severe unmet medical needs, is pleased to announce that CEO Martin Olin will be

presenting at the Carnegie Virtual Nordic Healthcare Seminar taking place today

at 15:15 CET.

The presentation will be made available on the Company's website in the

Investors section shortly after the presentation.

-Ends-

Contacts

Martin Olin

Chief Executive Officer, BerGenBio ASA

Rune Skeie

Chief FinancialOfficer, BerGenBio ASA

International Media Relations

Mary-Jane Elliott, Chris Welsh, Lucy Featherstone

ConsiliumStrategic Communications

+44 20 3709 5700

AboutBerGenBioASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing

transformative drugs targeting AXL as a potential cornerstone of therapy for

aggressive diseases, including immune-evasive, therapy resistant cancers. The

company's proprietary lead candidate, bemcentinib, is a potentially first-in

-class selective AXL inhibitor in a broad phase II clinical development

programme focused on combination and single agent therapy in cancer and COVID

-19. A first-in-class functional blocking anti-AXL antibody, tilvestamab, is

undergoing phase I clinical testing. In parallel, BerGenBio is developing a

potential companion diagnostic test to identify patient populations most likely

to benefit from AXL inhibition: this is expected to facilitate more efficient

registration trials supporting a precision medicine-based commercialisation

strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The

company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more

information, visit? www.bergenbio.com

AI Terminal